Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab Effect iN pOlymyalgia Rheumatica

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 50 years and 75 years included~* PMR-AS \> 10~* PMR according to the Chuang criteria~* Evolving since less than 12 months~* Without Horton disease~* Able to understand and accept the study~* Agree to sign the inform consent form~* Without GC, or at least during 1 month and stop since 7 days before the inclusion.~* Stable dose of Nonsteroidal anti-inflammatory since 4 weeks before the inclusion.~* Birth controlled during all the study and 6 months after~Exclusion Criteria:~* Disagree to participated~* Unable to understand the study~* Participation to an other study in the 3 months before the inclusion~* Treated by GC at 0.3mg/kg/d in the past 7 days~* Less than 50 years old or more than 75 years old~* Uncontrolled dyslipidemia, high blood pressure or cardiovascular disease~* Histories of important allergy~* Historically positive test or test positive at screening for HIV-1 antibody, hepatitis B surface antigen, or hepatitis C antibody.~* Abnormal screening blood test : leukocyte count less than 3.5 × 109 cells/L, neutrophil count less than 2 × 109 cells/L, hemoglobin level less than 85 g/L, platelet count less than 100 × 109 cells/L, or hepatic aminotransferase or alkaline phosphatase levels greater than 3 times the upper limit of normal~* Other inflammatory rheumatic disease or connective disease~* Clinical evidence of significant unstable or uncontrolled acute or chronic diseases not due to PMR (eg. Cardiovascular, pulmonary, hematologic, gastrointestinal, hepatic, renal, neurological, malignancy or infectious diseases)~* Current drug or alcohol abuse~* Patients treated with an immunosuppressive agents in the past 4 weeks~* Live/attenuated vaccine in the past 4 weeks~* Clinical symptoms of giant cell arteritis~* History of infection or infestation in the past 3 months~* Active tuberculosis~* Planned surgical procedure~* History of malignant neoplasm within the last 5 years, except for adequately treated cancer of the skin (basal or squamous cell)~* History or current tumoral hematological disease~* Severe allergic or anaphylactic reactions about one of the TCZ component~* Pregnant women during the study and six month after the end of the study~* Breast feeding mother~* Dysthyroidia~* Unstable treatment by statin in the past 3 months~* Parkinson disease~* Fibromyalgia~* Peripheric arthritis~* Articular chondrocalcinosis or hydorxyapatites rhumatisms

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TCZ (Type: EXPERIMENTAL): Tocilizumab at week 0, week 4 and week 8 8mg/kg at each perfusion

Based on this trial design, predict the completion outcome and termination type (if applicable).